Asuragen, Inc.

Newly launched Asuragen closes series A funding of $49 million

Published in Lab Business Week, July 2nd, 2006

Asuragen, Inc. announces that it has secured $49 million in series A funding.

Asuragen, a spin-off of Ambion Inc., will dedicate the funds towards general operating needs and to pursue strategic licenses relating to the development of its cancer diagnostic and therapeutic programs.

This initial round of investment, led by San Francisco, California, based Telegraph Hill Partners, included Houston based Growth Capital Partners and other firms that invested in Ambion, Inc.

Rollie Carlson joins Asuragen as president from Abbott Laboratories, has extensive experience in molecular diagnostic and pharmaceutical business areas. Most...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry